Liquidia Corporation, a biopharmaceutical company with a focus on developing and commercializing products using its PRINT® Technology, is set to provide an update on its business at the BofA Securities Health Care Conference 2024. Michael Kaseta, the company’s Chief Operating Officer and Chief Financial Officer, will be speaking in a fireside chat that begins at 5:00 p.m. PT on May 14, 2024.
Investors and interested parties will have access to a webcast of the presentation by visiting Liquidia’s website at
Liquidia Corporation operates through two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Additionally, Liquidia Technologies is working on L606, a liposomal formulation of treprostinil for use in North America.
Liquidia PAH specializes in the commercialization of pharmaceutical products to treat pulmonary diseases and provides products such as generic Treprostinil Injection. For more information about Liquidia Corporation and their products, please visit
